OPKO Health Inc Q4 2025 Earnings Call: Strategic Divestitures and Promising Pipeline

OPKO Health Inc reported Q4 2025 earnings, with strong momentum in diagnostics and pharmaceuticals. The company completed the sale of its oncology division, positioned its diagnostics business for profitability, and advanced its Modex pipeline. OPKO has a strong cash position, bolstered by asset sales, partnership payments, and international pharmaceutical business contributions. However, diagnostics revenue declined YoY, and the company reported a consolidated operating loss of $38.3 million and net loss of $31.3 million. Total costs and expenses are expected to be high at $725-$750 million for 2026.